by\u00a0Jim H\u1d0fft\u00a0<\/p>\n\n\n\n
The United States District Court for the Northern District of Texas ruled against the Food and Drug Administration (FDA) in a high-profile case brought by the Public Health and Medical Professionals for Transparency (PHMPT).<\/p>\n\n\n\n
The decision mandates the FDA to release the Emergency Use Authorization (EUA) file for the Pfizer-BioNTech COVID-19 vaccine no later than June 30, 2025.<\/p>\n\n\n\n
The case stemmed from a Freedom of Information Act (FOIA) request by the PHMPT, which sought comprehensive data related to the Pfizer-BioNTech COVID-19 vaccine.<\/p>\n\n\n\n
The FDA initially claimed it would need up to 75 years to process and release the requested documents. However, the Court, presided over by Judge Mark Pittman, rejected this argument, citing the importance of government accountability.<\/p>\n\n\n\n
In late 2021, the U.S. Food and Drug Administration (FDA) faced significant public scrutiny after proposing a timeline that would extend the full release of documents related to the approval of Pfizer-BioNTech\u2019s COVID-19 vaccine over several decades.<\/a><\/p>\n\n\n\n This proposal emerged following a Freedom of Information Act (FOIA) request by the Public Health and Medical Professionals for Transparency (PHMPT), a group of scientists and public health professionals seeking comprehensive data on the vaccine\u2019s approval process.<\/p>\n\n\n\n The FDA initially suggested releasing 500 pages per month from a collection exceeding 300,000 pages, effectively delaying complete disclosure until around 2097. The agency cited limited staffing and the extensive volume of documents as reasons for this prolonged timeline.<\/p>\n\n\n\n In response to the backlash, U.S. District Judge Mark Pittman in Fort Worth, Texas, issued a ruling in January 2022 that significantly shortened the FDA\u2019s proposed timeline.<\/p>\n\n\n\n